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Autosomal dominant renal hypomagnesemia, associated with hypocalciurea, has been linked to a G to A mutation at nucleotide position 121 in
the FXYD2 gene, resulting in the substitution of Gly with Arg at residue 41 of the protein. FXYD2, also called the Na,K-ATPase γ-subunit, binds
to Na,K-ATPase and influences its cation affinities. In this paper, we provide evidence for the molecular mechanism underlying the dominant
character of the disorder. Co-immunoprecipitation experiments using tagged FXYD2 proteins demonstrated that wild type FXYD2 proteins
oligomerise. Moreover, FXYD2-G41R also shows oligomerisation with itself and with the wild type protein. In the case of FXYD2-G41R,
however, formation of homo-oligomers was prevented by addition of DTT or introduction of the C52A mutation. Finally, we demonstrated that
artificial glycosylation of the wild type FXYD2 is reduced when co-expressed with FXYD2-G41R. These data indicate that binding of FXYD2-
G41R to wild type FXYD2 subunit might abrogate the routing of wild type FXYD2 to the plasma membrane thus causing the dominant nature of
this mutation.
© 2007 Elsevier B.V. All rights reserved.Keywords: Na,K-ATPase; FXYD2; Hypomagnesemia1. Introduction
Na,K-ATPase is an integral membrane protein, responsible
for the transport of Na+ and K+ ions across the cell membrane.
Na,K-ATPase consists of a catalytic α-subunit and a chaperone
β-subunit. In some tissues, like the kidney, however, a third
non-obligatory subunit is present. In 1978 Forbush et al. [1]
identified this small polypeptide that could be labeled with an
ouabain derivate and that directly associated with Na,K-⁎ Corresponding author. Tel.: +31 24 3614639; fax: +31 24 3614214.
E-mail address: J.Koenderink@ncmls.ru.nl (J.B. Koenderink).
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doi:10.1016/j.bbamem.2007.10.009ATPase. This third subunit, also called the Na,K-ATPase γ-
subunit, is one of seven mammalian members of the FXYD
family [2]. FXYD proteins are small type I membrane proteins
that all contain the FXYD motif and show a tissue-specific
expression pattern.
FXYD2 is expressed in the nephron. Although its exact
localization has been the subject of various studies, the results
seem to be somewhat at variance [3–5]. Recent research, how-
ever, indicates different distribution patterns for the two splice
variants of FXYD2 (FXYD2a and FXYD2b), and differences in
distribution between the outer and inner medulla of the rat
kidney [6]. Studies have shown that FXYD2 can change the Na,
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manner [3,4] and that it reduces the apparent affinity for Na+
[7,4]. In addition, it has been shown that FXYD2 regulates the
apparent affinity for ATP [5].
The two splice variants of FXYD2 differ in their seven
N-terminal residues but otherwise have identical chains [8,9].
It has been shown that at any given time Na,K-ATPase asso-
ciates exclusively with either FXYD2a or FXYD2b [10]. If the
FXYD2 subunit is not associated with Na,K-ATPase it will not
remain stable and is not efficiently transported to the plasma
membrane [3]. Studies indicate that the transmembrane domain
of FXYD2 binds to the groove formed by M2, M6, and M9 of
the Na,K-ATPase α-subunit [11], whereas the location of the
cytoplasmatic part is still questionable [12]. In addition, it
appears that the extracellular loop between M7 and M8 is the
focal region for γ–α–β interactions [13]. Mahmmoud et al.
[14] could isolate FXYD2 oligomers when the detergent so-
dium dodecylsulphate (SDS) was replaced by perfluoro-octa-
noic acid (PFO, a detergent that tolerates weak interactions)
during polyacrylamide gel electrophoresis. Furthermore, syn-
thetic peptides comprising the FXYD2 transmembrane region
self-associate in PFO [15].
Previously we reported a heterozygous 121G→A mutation
in the FXYD2 gene, leading to a G41R substitution in FXYD2,
as the cause of dominant renal hypomagnesemia associated with
hypocalciuria [16]. It has been shown that the G41R mutant fails
to interact with Na,K-ATPase and does not travel to the plasma
membrane when expressed in Xenopus laevis oocytes or HeLa
cells [17,18]. Exactly how a mutation in FXYD2 induces hypo-
magnesemia as observed in patients is, however, still not known.
It is also unclear how this heterozygous mutation can cause a
dominant phenotype as we previously reported that the disorder
is not caused by haploinsufficiency [16]. The aim of the present
study was to provide a mechanism for the dominant nature of
autosomal dominant renal hypomagnesemia. We show that this
dominance might be explained by impaired routing of wild type
FXYD2 due to oligomerisation of wild type and mutated
FXYD2 proteins.
2. Materials and methods
2.1. Construction of expression constructs
pTLN constructs coding for the N-terminally FLAG-tagged (DYKDDDDK)
and N-terminally VSV-tagged (YTDIEMNRLGK) human FXYD2a were used
for the X. laevis oocyte expression system [17]. The rat Na,K-ATPase α1- and
β1-subunits, were subcloned into the pTLN vector, suitable for the X. laevis
oocyte expression system. Site-directed mutagenesis was used to generate the
mutants described in this paper. All introduced mutations were verified by
sequencing.
2.2. Expression in X. laevis oocytes
X. laevis were sacrificed and parts of the ovaries were removed. Oocytes
were isolated by incubation for 2 h in modified Ringer's solution (90 mM NaCl,
2 mM KCl, 2 mM CaCl2, 5 mMMOPS, pH 7.4, 30 units/l penicillin and 30 mg/
l streptomycin) containing 2 mg/ml collagenase A. Prophase-arrested oocytes of
stages V and VI were selected for cRNA injection. cRNA synthesis was carried
out with the SP6-mMessage mMachine kit (Ambion, Austin, TX); HpaI-line-
arized pTLN vectors were used as templates. For the expression of the α-, β-,and γ-subunits, oocytes were injected with 15 ng, 2 ng, and 2 ng, respectively, of
the corresponding cRNAs. After injection, the oocytes were incubated for 3 days
at 18 °C in modified Ringer's solution [19].
2.3. Two-electrode voltage clamp
Two-electrode voltage clamp experiments were essentially performed as
described by Koenderink et al. [19]. Before measurements, oocytes were kept for
30 min in LS buffer (110 mMNaCl, 2.5 mMNa-citrate, 10 mMMOPS, Tris, pH
7.4) and 30 min in PS buffer (100 mM NaCl, 1 mM CaCl2, 20 mM tetra-
ethylammonium chloride (TEACl), 5 mM BaCl2, 5 mM NiCl2, 5 mM MOPS/
Tris (pH 7.4)) to elevate intracellular Na+ concentration. Measurements in the
absence of K+ were performed in Na+ test solution (100 mM NaCl, 20 mM
TEACl, 5 mM BaCl2, 5 mM NiCl2, 5 mM MOPS/Tris (pH 7.4) and 10 μM
ouabain to inhibit endogenous Na,K-ATPase). For K+ titration experiments and
stationary pump current recordings, 0.3–10 mMK+ were replaced for equimolar
amounts of Na+. Heterologously expressed Na,K-ATPase was inhibited by
10 mM ouabain during control measurements. Experiments were carried out at
room temperature (22–24 °C). To determine the apparent K0.5 values (apparent
K+ affinity (K1/2K
+) for stimulation of Na+/K+ pump current by extracellular
[K+], the amplitudes of stationary currents measured for a series of membrane
potentials (−160 mV to +60 mV) were fitted by a Hill equation with set Hill
coefficient of 1.6.
2.4. Preparation of total membranes
Oocytes were disrupted by passing them ca. 20 times through a standard
200 μl Gilson pipette in homogenization buffer (10 μl/oocyte; 250 mM sucrose,
0.5 mM EDTA, 5 mM Tris/HCl pH 7.4, and “Complete Protease Inhibitor”
(according to the instructions of the manufacturer, Roche Diagnostics GmbH,
Mannheim, Germany)). The yolk granules were removed by centrifugation
(1000 ×g, 4 °C, 3 min) and the supernatant was collected in a new tube. This step
was repeated twice. Subsequently, the membranes (plasma membranes and
intracellular membranes) were pelleted by centrifugation (16,000 ×g, 4 °C,
30 min). Finally, the pellet was resuspended in homogenization buffer (4 μl/
oocyte) and the samples were stored at −20 °C.
2.5. Immunoprecipitation
Immunoprecipitation was essentially performed as described by Garty et al.
[10]. 40 μl of total membranes (ca. 10 oocytes) was added to 60 μl buffer I
(33.3 mM Tris–HCl (pH 7.4), 1.67 mM EDTA, 33.3 mM NaCl, 0.167 mg/ml
oligomycin to force Na,K-ATPase in a conformation favorable for FXYD2
binding, and 1 tablet ‘Complete Protease Inhibitor’ (Roche)/10 ml) and
incubated 30 min at 4 °C. 100 μl buffer II (20 mM Tris–HCl (pH 7.4), 1 mM
EDTA, 20 mM NaCl, 0.1 mg/ml oligomycin, 2 mg/ml C12E10, and 1 tablet of
‘Complete Protease Inhibitor’ (Roche)/10 ml) was added and incubated for
20 min at 4 °C under repeated vortexing (5 min intervals). After adding 800 μl of
buffer III (20 mM Tris–HCl, 1 mM EDTA, 100 mM NaCl, 0.1 mg/ml
oligomycin, and 1 mg/ml C12E10) solutions were centrifuged (16,000 ×g at 4 °C,
30 min). The supernatant was added to 25 μl ANTI-FLAGM2-Agarose affinity
gel beads (Sigma-Aldrich) and rotated overnight at 4 °C. Beads were washed 5
times in cold buffer IV (20 mM Tris–HCl, 1 mM EDTA, 100 mM NaCl, and
0.2 mg/ml C12E10), solubilized in 30 μl Laemmli buffer [20] and analyzed on
15% SDS-PAGE gels.
2.6. Western blotting
Total membrane fractions of X. laevis oocytes were solubilized in Laemmli
buffer and analyzed on SDS-PAGE gels containing 15% acrylamide according
to Laemmli [20]. For immunoblotting, the separated proteins were transferred to
Immobilon-P membranes (Millipore, Co., Bedford, MA). The FXYD2-subunits
were detected with the anti-FLAG antibody M2 (Sigma-Aldrich) or the anti-
VSV-G antibody P4D5 [21], whereas the α-subunit of Na,K-ATPase was de-
tected with antibody C356-M09 [19]. Primary antibodies were detected using an
anti-mouse or anti-rabbit secondary antibody, labeled with horseradish peroxi-
dase (DAKO A/S, Denmark).
400 E.R. Cairo et al. / Biochimica et Biophysica Acta 1778 (2008) 398–4042.7. Glycosylation
Deglycosylation was performed on membranes isolated from oocytes (co-)
expressing wild type and G41R FXYD2 in which a G3N mutation was intro-
duced. 9 μl of membrane sample was denatured by adding 1 μl denaturation
buffer (5% SDS and 10% mercaptoethanol) after which the mixture was incu-
bated at 50 °C for 10 min. Subsequently 1.5 μl 500 mM sodium phosphate pH
7.5, 1.5 μl 10% NP-40, 1 μl water and 1 μl N-Glycosidase F was added (for
negative control glycosidase was replaced with water), incubated at 37 °C for 1 h
and analyzed on SDS-PAGE.Fig. 2. Interaction between Na,K-ATPase α, β, and γ. Membrane isolations,
immunoprecipitation, and immunoblotting were carried out as described under
Materials and methods. (A) Total membrane isolations of injected oocytes
expressing Na,K-ATPase subunits as indicated. (B) Co-immunoprecipitation
targeted against the FLAG-tag of the FXYD2 subunit revealing strongly
diminished interaction between the α-subunit and the γ-subunit containing the
G41R mutation compared to the wild type FXYD2 (n=3).3. Results
To determine the effect of a FLAG-tagged human FXYD2a
subunit on the apparent K+ affinity of Na,K-ATPase we inves-
tigated the voltage dependence of the stationary currents (I–V
curves) of Na,K-ATPase with and without FLAG-tagged
FXYD2 at different extracellular K+ concentrations. The current
in the absence of K+ was subtracted from those in the presence
of 0.15, 0.5, 1.5, 5, or 15 mM K+. Upon the addition of 10 mM
ouabain the currents ceased and baseline was restored, indi-
cating that the currents were driven by heterologously expressed
Na,K-ATPase. The apparent K0.5 value for stimulation of Na,
K-ATPase current by extracellular K+ was determined from the
voltage dependence of stationary currents at different [K+] (see
“Materials and methods”). The (voltage-dependent) K0.5 of the
wild type enzyme at 100 mM Na+ had a minimum of 0.4 mM
at −20 mV and increased to 0.6 mM at 60 mV and 2.4 mM at
−160 mV, respectively (Fig. 1). In the presence of FXYD2 the
enzyme had its maximal apparent K+ affinity at −40 mV
(K0.5=0.5 mM). This value decreased when the plasma
membrane was depolarized (K0.5=1.0 mM at 60 mV) or
hyperpolarized (K0.5=1.7 mM at −180 mV; see Fig. 1).
FXYD2 increased the apparent K+ affinity of Na,K-ATPase at
high negative membrane potentials and decreased the apparentFig. 1. Voltage dependence of the K0.5 value of K
+-dependent current stimu-
lation in injected Xenopus laevis oocytes expressing Na,K-ATPase α-, β-, and
γ-subunits as indicated, at 100 mM Na+. The K0.5 values were determined by
fitting the voltage dependence of extracellular K+-activated Na,K-ATPase
current with a Hill equation for the Na,K-ATPase, with and without FXYD2
(Average of 5–6 oocytes (2 batches)±SEM). The presence of FXYD2 clearly
shifts the range of the apparent K0.5 values.K+ affinity at less negative and positive membrane potentials,
similarly as previously reported [3,7]. When FXYD2 was re-
placed with FXYD2-G41R, however, the oocytes showed high
leak conductance and no reliable electrophysiological results
could be obtained (data not shown). The results from the oocytes
injected with wild type FXYD2 confirm that our expression
system is functional, and that the presence of the FLAG-tag most
likely has no adverse effect on the human FXYD2 protein.
Previous studies have demonstrated that FXYD2 binds to
Na,K-ATPase [3,7,10,22–24]. To further validate our experi-
mental setup we solubilized the total membrane fraction of
Xenopus oocytes with C12E10 according to Garty et al. [10] and
immunoprecipitated the FLAG-tagged FXYD2 subunit with an
anti-FLAG antibody. The samples were subjected to SDS-
PAGE and immunoblotting after which the presence of both
FXYD2 and the Na,K-ATPase α-subunit was visualized with
specific antibodies. The Na,K-ATPase α-subunit was co-ex-
pressed with the wild type FXYD2 and the FXYD2-G41R
(Fig. 2A). Co-immunoprecipitation of theNa,K-ATPaseα-subunit
is evident when it is co-expressed with the wild type FXYD2
protein (Fig. 2B, lane 2). When the α-subunit is co-expressed
with the G41R mutant, however, the amount of detected asso-
ciation is strongly diminished (Fig. 2B, lane 3) indicating that the
G41R mutation destabilizes association between FXYD2 and
Na,K-ATPase.
The lack of binding of the FXYD2-G41R mutant to Na,
K-ATPase, however, cannot explain the dominant nature of
autosomal dominant renal hypomagnesemia. We previously
presented evidence that deletion of a single FXYD2 allele does
not give rise to hypomagnesemia [16]. This finding together
with previous observations that FXYD2 can form oligomers
[14,15] led us to hypothesize that the mutant FXYD2 subunit
could have an effect on the routing of the wild type FXYD2
subunit. To investigate the interaction between FXYD2 sub-
units, we carried out co-immunoprecipitation experiments using
differentially tagged FXYD2 proteins. Both wild type and
FXYD2-G41R proteins were expressed in X. laevis oocytes
(Fig. 3A). Co-immunoprecipitation experiments showed that
VSV-tagged FXYD2 proteins are co-immunoprecipitated with
Fig. 3. Oligomerisation of FXYD2. Membrane isolations, immunoprecipitation,
and immunoblotting were carried out as described under Materials and methods.
(A) Total membrane isolations of injected oocytes showing expression of all
proteins. (B) Immunoprecipitation targeted against the FLAG-tag shows oligo-
merisation of the FLAG-tagged and VSV-tagged FXYD2 proteins (n=3).
Fig. 5. Oligomerisation of FXYD2 under reducing and non-reducing conditions.
Expression, membrane isolations, immunoprecipitation, and immunoblotting
were carried out as described under Materials and methods. FLAG-tagged
FXYD2 was immunoprecipitated with and without DTT. The immunoprecip-
itate was blotted and the presence of FLAG-tagged and VSV-tagged FXYD2
proteins was detected with specific antibodies. Addition of DTT to the
immunoprecipitation reaction resulted in the abolishment of oligomerisation
between FXYD2-G41R mutants and showed an apparent decrease in
oligomerisation between the wild type/G41R mutants. The wild type FXYD2
situation seemed unaffected (n=3).
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(Fig. 3B), indicating that they form oligomers consisting of at
least two subunits, irrespective of the absence or presence of the
G41R mutation.
To investigate whether the conserved cysteine at position 52
had any effect on oligomerisation the reducing agent dithio-
threitol (DTT) was excluded during the total membrane sample
preparation for SDS-PAGE. The immunoblot not only showed
the monomeric FXYD2 signal around 15 kDa, but also bands
with decreased mobility, of which a band around 25–30 kDa in
particular suggests the presence of FXYD2 oligomers (Fig. 4).
The presence of N-ethylmaleimide (NEM), a well-known cy-
steine alkylator, during the membrane isolation steps did not
change these results (data not shown), indicating that the disul-
phide bridges are not an artifact formed during the membrane
isolation steps. These data suggest that in our experiments the
formation of a disulphide bridge is involved in FXYD2
oligomerisation.
To study the role of this disulphide bridge, co-immunopre-
cipitation experiments were performed in the presence or ab-
sence of 1 mM DTT during the entire immunoprecipitationFig. 4. Native SDS-PAGE electrophoresis of the FXYD2 subunit. Total
membrane isolations and immunoblotting were performed as described in
Materials and methods with and without DTT as indicated. Under non-reducing
conditions FLAG-tag signals can be seen at heights indicating the presence of
FXYD2 oligomers (n=2).reaction. Without DTT the results were the same as in the
previous immunoprecipitation experiments with all subunits
showing association regardless of the G41Rmutation. Under the
reducing conditions wild type subunits still show association and
wild type/mutant FXYD2 proteins also still co-immunoprecipi-
tated (Fig. 5, lanes 5–7), but FXYD2-G41R proteins no longer
show co-immunoprecipitation (Fig. 5, lane 8).
Since there is only a single cysteine in FXYD2 that can
account for the previous results, we mutated Cys52 into an Ala
and repeated the co-immunoprecipitation experiments. The ex-
pression level of this mutated FXYD2 protein was similar to
that of the wild type (Fig. 6, lanes 1–4). The interaction between
this FXYD2-C52A and the wild type FXYD2 is sufficient for
co-immunoprecipitation (Fig. 6, lane 5). As soon as the G41RFig. 6. Oligomerisation of FXYD2-C52A mutants. Membrane isolations,
immunoprecipitation, and immunoblotting were carried out as described under
Materials and methods. Mutation of Cys52 into Ala shows the same effect as
adding DTT to the reaction as seen in Fig. 5, indicating the role of Cys52 in
forming FXYD2 oligomers (n=3).
Fig. 7. Glycosylation of FXYD2-G3N and FXYD-G41R/G3N. An artificial
glycosylation site was introduced in wild type FXYD2 and FXYD-G41R.
Membranes of Xenopus laevis oocytes injected with equal amounts of cRNA of
FXYD2-G3N, FXYD-G41R/G3N and their combination were treated with
PNGase F and immunoblotted as described under Materials and methods. The
pixel density of the three experiments was averaged (±SEM) and plotted below a
typical immunoblot.
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immunoprecipitation diminished (Fig. 6, lanes 6 and 7). When
the G41R mutation was present in both FXYD2 subunits in
addition to the C52A mutation no interaction was apparent
(Fig. 6, lane 8), similar to the co-immunoprecipitation experi-
ments using DTT.
We previously demonstrated with immuno-cytochemical
methods that the G41R-mutated FXYD2 is misrouted in the
present system [17]. Due to the balance between over-expression
and the detection limit we could not show with immuno-cyto-
chemical methods that wild type FXYD2 is absent in the plasma
membrane when G41R-mutated FXYD2 is co-expressed. To
demonstrate that FXYD2-G41R influences FXYD2-WT routing
we introduced a glycosylation site (G3N) in both FXYD2 pro-
teins. These mutants were (co-)expressed in X. laevis oocytes
and the isolated membranes were treated with PNGase F and
analyzed on SDS-PAGE (Fig. 7). The FXYD2-G3N showed
decreased mobility on SDS-PAGE, which was absent after
treatment with PNGase F, indicating glycosylation of the
protein. The FXYD2-G41R/G3N protein showed less glycosyl-
ation.When both the wild type FXYD2 and the G41Rmutant are
co-expressed, the amount of glycosylation is reduced. In
addition, the pattern of glycosylation of the wild type and
mutant FXYD2 seems to differ. This might be due to core
glycosylation of the mutant versus full glycosylation of the wild
type enzyme.
4. Discussion
In this study we show that oligomerisation of FXYD2 might
explain the dominant character of renal hypomagnesemia. Ourstudies demonstrate that the G41R-mutated human FXYD2
subunit is not able to interact with Na,K-ATPase. We also
provide evidence for the formation of FXYD2 oligomers that in
the first instance are unaffected by the G41Rmutation. However,
in the presence of DTT, or when Cys52 in FXYD2 was mutated,
the interaction between two FXYD2-G41R molecules was
absent, whereas the interaction between wild type FXYD2 and
FXYD2-G41R was still present, but weakened. In addition,
artificial glycosylation of FXYD2-WT is decreased when co-
expressed with FXYD2-G41R, indicating that routing of wild
type FXYD2 could be hampered due to the co-expression of
FXYD2-G41R. Binding of FXYD2-G41R to the wild type
FXYD2 subunit therefore may abrogate the regulation of Na,K-
ATPase and thereby underlie the dominant nature of this
mutation.
We demonstrated that the human FLAG-tagged FXYD2
protein influences the apparent K+ affinity in a membrane
potential dependent manner. The effect is in agreement with
published results for wild type FXYD2 [3]. FXYD2 was shown
to increase the apparent K+ affinity of Na,K-ATPase at high
negative membrane potentials and decrease the apparent K+
affinity at less negative membrane potentials, suggesting a shift
in the E1–E2 equilibrium towards the E1 conformation [7].
Though we cannot exclude the possibility of other FXYD
subunits being endogenously expressed, it is not very likely that
they influenced the results obtained, because we compared
oocytes that heterologously express FXYD2 with those that do
not express FXYD2. Introduction of the G41R mutation in
FXYD2, that was identified in patients with hypomagnesemia
[16], resulted in oocytes with a high leak conductance. We were
not able to determine the apparent affinity for K+ in these
oocytes from different current experiments. Previously, Cram-
bert et al. showed that the introduction of the homologous G40R
mutation into FXYD7 also induced increased mortality in
injected oocytes [25]. This indicates that the over-expression of
these mutants disrupts normal physiological processes in the X.
laevis system and thus making electrophysiological experi-
ments more difficult.
Since the FXYD family members possess their highest level
of homology within their transmembrane domains and Gly41 is
conserved among all known FXYD proteins, this amino acid is
likely to be structurally and/or functionally significant. We
demonstrated that FXYD2 also binds to the Na,K-ATPase
α-subunit and that binding of FXYD2-G41R to the α-subunit is
virtually abolished, which is in agreement with the findings of
Pu et al. [18].
This is the first report that demonstrates oligomerisation of
recombinant FXYD2 proteins by co-immunoprecipitation. It
was shown previously that pig renal FXYD2 and synthetic
peptides that comprise the FXYD2 transmembrane region oli-
gomerise when the detergent sodiumdodecylsulphate (SDS)was
replaced by perfluoro-octanoic acid (PFO) in polyacrylamide gel
electrophoresis [14,15]. Co-immunoprecipitation experiments,
however, provided no evidence for complexes containing more
than one FXYD protein for each αβ-complex [10,12]. In this
regard it is interesting to compare the function of FXYD2 with
the regulatory role of phospholamban (PLN) on the SERCA
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state and the pentameric PLN represents a reservoir that disso-
ciates to provide regulatory monomeric PLN subunits [26]. In
addition, the oligomeric state of FXYD2may explain the finding
that this small protein has been reported to exhibit cation channel
activity [27] by forming channels in the plasma membrane.
We observed co-immunoprecipitation between FXYD2-
G41R subunits and also between FXYD2-G41R and wild
type subunits. In contrast to our results, Therein and Deber,
did not find oligomerisation of G41R mutants in their study
using synthetic peptides comprising the TM domain of
FXYD2 [15]. This discrepancy could be explained by the
absence of intracellular and extracellular FXYD2 domains in
their study. Indeed, our study showed that the presence of a
Cys residue at position 52 in the cytosolic domain is
important for the stable interaction of G41R-FXYD2. This
Cys is highly conserved among the FXYD family members
(only in FXYD5 it is a Glu) and might play a stabilizing role
in oligomerisation. Our results indicate that the introduction
of the G41R mutation in the transmembrane domain weakens
the interaction between the subunits, yet in non-reducing
conditions the disulphide bridge is still capable of yielding
normal association between subunits and thus normal co-
immunoprecipitation. Only when both sub
units contain the G41R mutation in a reducing environment,
we do not observe co-immunoprecipitation. Although the
existence of a disulphide bridge in the cytosol is debatable,
our studies indicate that without the formation of a disulphide
bridge, FXYD2-G41R subunits are still capable of forming
oligomers with wild type subunits. Moreover, in the absence
of disulphide bridges the pool of monomeric G41R mutants is
not diminished by the formation of FXYD2-G41R oligomers.
Therefore, more monomeric FXYD-G41R subunits are
available to associate with wild type subunits.
The dominant mechanism of the disorder was investigated in
two individuals with an 11q23.3-ter deletion that includes the
FXYD2 gene. Both had normal serum Mg2+ level, showing
that rather than haploinsufficiency, the presence of FXYD2-
G41R causes hypomagnesemia, consistent with a dominant-
negative mechanism [16]. The formation of FXYD2 oligomers
could explain the dominant nature of the disease. Whereas the
wild type FXYD2 protein is present at the plasma membrane the
G41R mutant is not [17,18]. With the introduction of an arti-
ficial glycosylation site in both FXYD2 subunits (G3N), we
showed that only the wild type subunit is fully glycosylated,
indicating that it is completely processed. The G41R mutant is
hardly glycosylated and the pattern of glycosylation is altered.
This altered pattern might be due to core glycosylation that is
characteristic for ER retention. These observations might imply
that the G41R mutant is retarded before full glycosylation
occurs. When both wild type and G41R proteins are expressed
the glycosylation is also reduced and the pattern altered. It is
likely to assume that the mutated FXYD2 protein binds to the
wild type and prevents the routing of the wild type FXYD2 to
the plasma membrane.
In this study we show that FXYD2 wild type and G41R
proteins are present in an oligomeric status. The amino acidsthat form the oligomerisation interface and the exact cellular
location of hetero-oligomers of wild type and FXYD2-G41R
remain to be established in future experiments. The oligomer-
isation experiments together with the glycosylation experiments
support our hypothesis that binding of FXYD2-G41R to wild
type FXYD2 subunit might abrogate the routing of wild type
FXYD2 to the plasma membrane thus causing the dominant
nature of this mutation.
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